| Literature DB >> 16277655 |
Borys R Krynyckyi1, Michail K Shafir, Suk Chul Kim, Dong Wook Kim, Arlene Travis, Renee M Moadel, Chun K Kim.
Abstract
Current trends in patient care include the desire for minimizing invasiveness of procedures and interventions. This aim is reflected in the increasing utilization of sentinel lymph node biopsy, which results in a lower level of morbidity in breast cancer staging, in comparison to extensive conventional axillary dissection. Optimized lymphoscintigraphy with triangulated body marking is a clinical option that can further reduce morbidity, more than when a hand held gamma probe alone is utilized. Unfortunately it is often either overlooked or not fully understood, and thus not utilized. This results in the unnecessary loss of an opportunity to further reduce morbidity. Optimized lymphoscintigraphy and triangulated body marking provides a detailed 3 dimensional map of the number and location of the sentinel nodes, available before the first incision is made. The number, location, relevance based on time/sequence of appearance of the nodes, all can influence 1) where the incision is made, 2) how extensive the dissection is, and 3) how many nodes are removed. In addition, complex patterns can arise from injections. These include prominent lymphatic channels, pseudo-sentinel nodes, echelon and reverse echelon nodes and even contamination, which are much more difficult to access with the probe only. With the detailed information provided by optimized lymphoscintigraphy and triangulated body marking, the surgeon can approach the axilla in a more enlightened fashion, in contrast to when the less informed probe only method is used. This allows for better planning, resulting in the best cosmetic effect and less trauma to the tissues, further reducing morbidity while maintaining adequate sampling of the sentinel node(s).Entities:
Year: 2005 PMID: 16277655 PMCID: PMC1308847 DOI: 10.1186/1477-7800-2-25
Source DB: PubMed Journal: Int Semin Surg Oncol ISSN: 1477-7800
Figure 1(A*) TOP: Labeled as a "typical" lymphoscintigraphy finding in an article disputing the value of lymphoscintigraphy, the lateral view depicts the poor quality of injection and imaging technique [37]. The injection site is represented by the solid arrow, the faint, barely visible SN by the open arrow. (B) BOTTOM: Right lateral view of typical/average result from optimized injection and imaging protocol showing injection sites (solid arrow) and bright sentinel node (open arrow) as well as lymphatic channel leading to sentinel node [38]. In many cases, even much brighter nodes than depicted in B are found. *Reprinted from Am J Surg. 177, Burak WE Jr, Routine preoperative lymphoscintigraphy is not necessary prior to sentinel node biopsy for breast cancer, 445–449., 1999, with permission from Elsevier Ltd.; Excerpta Medica Inc . [37].
Figure 2Schematic of triangulated patient body marking technique. Different colored permanent markers are used to place reference points on the patient's body corresponding to the location of a sentinel node along a particular projection. With this form of triangulation, the location of the sentinel nodes can be defined in 3 dimensions along appropriate triangulation lines. The arm is maintained in the surgical position (90°) to eliminate shifting of skin markings*. The rotation of the torso referenced to the floor must be kept constant during both imaging and surgery for the relationships to remain valid, or compensated for by equally shifted projections if rotation is desired during surgery [40]. *Adapted, revised and used with permission from Radiographics . 2004;24:121–145. Krynyckyi BR, et al. RSNA Publications, Oak Brook, IL. [ref. 38].
Comparisons of average chronic pain and numbness/paresthesia morbidity between LS groups (+) performing lymphoscintigraphy and non LS groups (-) not performing lymphoscintigraphy in patients undergoing SLNB using radiotracer or using only dye. In general, studies using lymphoscintigraphy have much lower levels of chronic sensory morbidity. Data from original reference by Kim SC et al. [41].
| Lymphoscintigraphy (+) Performed | Lymphoscintigraphy (-) Not Performed | ||||||
| Mor (%) | Total Pt (N) | References | Mor (%) | Total Pt (N) | References | #p-value | |
| Pain (>9m) | 13.77% | 1365 | 1,2,4,9,10,11,14,20 | 28.67% | 143 | 6 | < 0.0001 |
| Numbness/Paresthesia (>9m) | 12.56% | 677 | 1,4,9,11,13,14,17,20 | 23.14% | 229 | 3,6,18 | 0.0003 |
*Adapted, revised, and used with permission from Kim SC et al: Using the intraoperative hand held probe without lymphoscintigraphy or using only dye correlates with higher sensory morbidity following sentinel lymph node biopsy in breast cancer: A review of the literature. World J Surg Oncol 2005, 3:64. [41].
#Statistics used to generate the p value: Fisher's exact test (2-tailed). A result was considered to be significant only if the p-value was lower than 0.05.
Updated comparisons of average chronic pain and numbness/paresthesia morbidity between LS groups (+) performing lymphoscintigraphy and non LS groups (-) not performing lymphoscintigraphy in patients undergoing SLNB using radiotracer or using only dye. In general, studies using lymphoscintigraphy continue to have much lower levels of chronic sensory morbidity. Updated data by incorporation of four new references [21,22,23,24].
| Lymphoscintigraphy (+) Performed | Lymphoscintigraphy (-) Not Performed | ||||||
| Mor (%) | Total Pt (N) | References | Mor (%) | Total Pt (N) | References | #p-value | |
| Pain (>9m) | 14.32% | 1508 | 1,2,4,9,10,11,14,20,22,24 | 28.67% | 143 | 6 | < 0.0001 |
| Numbness/Paresthesia (>9m) | 9.22% | 1052 | 1,4,9,11,13,14,17,20,23,24 | 23.17% | 315 | 3,6,18,21t | < 0.0001 |
*Adapted, revised, updated and used with permission from Kim SC et al: Using the intraoperative hand held probe without lymphoscintigraphy or using only dye correlates with higher sensory morbidity following sentinel lymph node biopsy in breast cancer: A review of the literature. World J Surg Oncol 2005, 3:64. [41].
tUse of LS is variable/suboptimal [21]. See text for details.
#Statistics used to generate the p value: Fisher's exact test (2-tailed). A result was considered to be significant only if the p-value was lower than 0.05.
| - Reduces morbidity compared to probe only method. |
| - Reduces short and long term costs of treatment resulting from morbidity. |
| - Facilitates minimal invasiveness, improving cosmetic results. |
| - Assists surgeons in planning their approach and harvesting the SN. |
| - Provides additional guidance for surgeons who are learning the SLNB technique. |
| - Reduces overall surgical costs (anesthesia time, operating room utilization) by shortening surgery. |
| - Provides a wide field of view survey covering multiple lymph node basins simultaneously improving staging. |
| - Diffusion fields emanating from injection sites are defined and assessed for partly hidden nodes by scaling. |
| - The effects of breast displacement maneuvers are easily assessed. |
| - Delineates multiple SN nodes, their position and intensity along lymphatic channels, time of appearance. |
| - Delineates intervening nodes in unexpected positions when prominent lymphatic channels are present. |
| - Estimates the position of the SNs in the body from triangulated body marking (TBM). |
| - Surface contamination and other quality control issues are easy to detect and implement. |
| - Dynamic imaging is possible and its potential benefits in select cases. |
| - Assesses the intensity of the SN for next day surgery and determines the need for additional injections. |
| - Alerts to a failed node visualization (tumor replacement) and the possibility of a more extensive ALND. |
| - Delineates reverse echelon nodes, persistent lymphatic pools/dilations, end-on effects. |
| - Guides the planning of radiation ports with the inclusion of internal mammary chains when present. |
| - Sitting views can resolve clumped nodes, not possible with the probe after anesthesia. |
| - Improved localizing performance in obese patients compared to the probe before incision. |
| - Reduces the chance of un-harvested SNs (false negatives) through comparisons (numerical/positional/intensity) with images. |
| - Additional cost of procedure. |
| - Technically effort-intensive to fully optimize. |
| - Can delay surgery if not scheduled appropriately. |
| - Additional patient time required and any associated discomfort during imaging. |
| - Inadequate reimbursement for those performing it. |
| - High resolution low energy cast (non-foil) collimator [38,96,97]. |
| - 128 × 128 matrix-dynamic, 256 × 256 matrix-static. |
| - Upwardly offset 99mTc energy windows and separate 57Co energy windows (122 kev) [38,43,77,96]. |
| - Decayed 57Co sheet source transmission outlining to limit exposure [38,96]. |
| - Anesthetic cream (EMLA) applied to injection sites for 30+ minutes [38,43,77]. |
| - Hybrid radiotracer injection technique: Concurrent perilesional (2–4 ml biased away from the axilla) and areolar-cutaneous "junction" injections " |
| - High specific activity preparation, 100% filtered [130]. |
| - Lidocain added to sulfur colloid syringe for additional pain control [38,43,77]. |
| - Mild/short massage only [131]. |
| - Deeper sub-lesional injections for internal mammary SN visualization if deemed important [113]. |
| - Contamination control [77]. |
| - Optional post perilesional injection views. |
| - Dynamic lateral 100 frame 10 second images during areolar-cutaneous "junction" injection " |
| - Optional immediate post dynamic early static sitting/standing views (see below). |
| - Delayed supine anterior and oblique 45° views with the arm out in the 90° surgical position and lateral views with the arm up towards the head with triangulated body marking of anterior and oblique 45° views. |
| - 57Co sheet source transmission outlining of anterior and lateral views [38,43,96]. |
| - Sitting/Standing views highly recommended (see below). |
| - Perform perilesional injection followed by 30 minute (or more) delayed views followed by LB injection (dynamic see above). Alternately delete perilesional injections altogether (only inject LB). |
| - |
| - Tape breast displacement for small breasts, for large/pendulous breasts use sitting views (see below) [38,43,96]. |
| - Prone imaging [112], MOVA position [127], next day follow up views if two day. |
| - Avoid lead shielding the injection site [42,96,97]. |
| - See figure 2, [38,40,43]. |
| - Highly recommended end of study anterior and lateral sitting/standing views with arm out in the 90° surgical position with chest pressed up against collimator (best resolution), two 1 minute frames each position to address motion if it occurs [38,40,43,67-71,96]. Works best in large breasted women. |
| - Adjustment of upper level, gamma curve, pre-display low level data enhancement (pre-scale/contrast/threshold) and appropriate image summation [96]. |
| - Viewing dynamic sequences in cine mode [107]. |
| - Two sets of images for final supine views (marking views): with and without 57Co transmission scan (when performed) [38,96]. |
| - Print images large enough for surgeons to clearly see anatomy. Optionally print sitting views and/or dynamic sequences if important [38,96,107]. |
| - Timely and detailed communications with surgeon before surgery to discuss findings, meaning/convention of markings and complex patterns. Number of SN based on supine and standing views, appearance sequence and perceived intensity, 3-D position in body, any extra-axillary or intramammary nodes, dilations/ectasias. |